Press releases
- LivaNova Reports First-Quarter 2024 Results
- LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
- LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident
- LivaNova to Announce First-Quarter 2024 Results
- LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
- LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029
- LivaNova to Present at the Barclays Global Healthcare Conference
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 39.55 |
---|---|
High | 39.55 |
Low | 39.20 |
Bid | 38.92 |
Offer | 39.11 |
Previous close | 39.20 |
Average volume | 9.17 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of May 22 2024 20:49 BST.
More ▼